Join to View Full Profile
600 Highland AveMadison, WI 53792
Phone+1 608-265-1700
Fax+1 608-262-1982
Dr. Albertini is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1986 - 1991- University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1984 - 1986
University of Vermont College of MedicineClass of 1984
Certifications & Licensure
WI State Medical License 1985 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- America's Top Doctors for Cancer Castle Connolly, 2008-2013
Clinical Trials
- Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma Start of enrollment: 1999 May 01
- Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma Start of enrollment: 2005 May 01
- Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma Start of enrollment: 2007 Dec 17
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsAdministration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma.Mark R Albertini, Cindy L Zuleger, Erik A Ranheim, Oyewale Shiyanbola, Paul M Sondel
Melanoma Research. 2024-08-01 - 13 citationsNCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024.Susan M Swetter, Douglas Johnson, Mark R Albertini, Christopher A Barker, Sarah Bateni
Journal of the National Comprehensive Cancer Network. 2024-07-01 - Development of a next-generation sequencing protocol for the canine T cell receptor beta chain repertoire.Cindy L Zuleger, Rene Welch Schwartz, Irene M Ong, Michael A Newton, David M Vail
Veterinary Immunology and Immunopathology. 2024-02-01
Journal Articles
- The Age of Enlightenment in Melanoma ImmunotherapyMark Albertini, MD, BioMed Central
- E3611- A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High Dose Interferon-α2b in Advanced MelanomaArun Nagarajan, Mark R Albertini, Stuart Wong, Noel Laudi, Robert M Conry, Clinical Cancer Research
Press Mentions
New Clinical Trial for Advanced Melanoma Patients Seeks to Turn Tumors Against ThemselvesOctober 23rd, 2019
Wisconsin Physicians Honored for Cross-Specialty Collaboration to Advance Skin Cancer TreatmentSeptember 18th, 2019- The Age of Melanoma EnlightenmentAugust 16th, 2018
- Join now to see all
Grant Support
- Administration of intratumoral immunocytokine to activate immune rejection of spontaneous canine melanomaWM S. MIDDLETON MEMORIAL VETERANS HOSP2019–2025
- Clinical Academic Oncologist Training ProgramNational Cancer Institute2006–2008
- Vaccine Therapy AND/OR GM-CSF In Locally Advanced Or Metastatic MelanomaNational Center For Research Resources2006–2007
- High-Dose Ifn-Alpha-2b VS Cisplatin, Vinblastine, DTIC + IL-2 &Ifn In MelanomaNational Center For Research Resources2006–2007
- Phase I/IB Trial Of Hu14 18 IL 2 Fusion Protein In Patients W/ Gd2+ TNational Center For Research Resources1999–2002
- Immunization Using Particle Mediated Transfer Of GenesNational Center For Research Resources2000
- Phase I Ch14.18 And R24 MOAB And IL-2 For Patients With Gd2+/Gd3+National Center For Research Resources1996–1999
- Gene Therapy Of Melanoma By Particle BombardmentNational Cancer Institute1995–1999
- Tumor Infiltrating Lymphocytes In Breast Cancer EffusionNational Cancer Institute1987–1989
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
